Open AccessClinical relevance of an objective flow cytometry approach based on limit of detection and limit of quantification for measurable residual disease assessment in acute myeloid leukemia. A post-hoc analysis of the GIMEMA AML1310 trial
Author(s) -
Francesco Buccisano,
Raffaele Palmieri,
Alfonso Piciocchi,
Valentina Arena,
Luca Maurillo,
Maria-Ilaria Del Principe,
Giovangiacinto Paterno,
Maria-Antonietta Irno-Consalvo,
Tiziana Ottone,
Mariadomenica Divona,
Consuelo Conti,
Daniela Fraboni,
Serena Lavorgna,
William Arcese,
Maria Teresa Voso,
Adriano Venditti
Publication year - 2022
Publication title -
haematologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.782
H-Index - 142
eISSN - 1592-8721
pISSN - 0390-6078
DOI - 10.3324/haematol.2021.279777
Subject(s) - medicine , hazard ratio , confidence interval , minimal residual disease , myeloid leukemia , flow cytometry , stage (stratigraphy) , gastroenterology , oncology , univariate analysis , post hoc analysis , bone marrow , multivariate analysis , immunology , biology , paleontology
Using a multiparametric flow cytometry (MFC) assay, we assessed the predictive power of a threshold calculated applying the criteria of limit of detection (LOD) and limit of quantitation (LOQ) in adult patients affected with Acute Myeloid Leukemia (AML). This was a post-hoc analysis of 261 patients enrolled in the GIMEMA AML1310 prospective trial. According to the protocol design, using the predefined MRD threshold of 0.035% bone marrow residual leukemic cell (RLC) calculated on mononuclear cells, 154 (59%) were negative (MRD